Back to Journals » Neuropsychiatric Disease and Treatment » Volume 17

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience

Authors Montes JM, Montes P, Hernández-Huerta D

Received 23 December 2020

Accepted for publication 21 January 2021

Published 3 February 2021 Volume 2021:17 Pages 291—296

DOI https://doi.org/10.2147/NDT.S298005

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Jose M Montes,1 Paloma Montes,2 Daniel Hernández-Huerta3

1Psychiatry Service, CIBERSAM, IRYCIS, Hospital Universitario Ramóny Cajal, Madrid, Spain; 2Psychiatry Service, Hospital Universitario de Móstoles Madrid, Spain; 3Psychiatry Service, Hospital Universitario Ramón y Cajal, Madrid, Spain

Correspondence: Jose M Montes
Psychiatry Service, Hospital Universitario Ramón y Cajal, Carretera Colmenar Km 9,1, Madrid, 28034, Spain
Tel +34 91 336 9152
Fax +34 91 336 8483
Email j_m_montes@hotmail.com

Abstract: There are still some unmet needs in the treatment of schizophrenia like the persistence of negative symptoms. Cariprazine is a new-generation antipsychotic with partial agonism of the dopamine receptors, distinct from other antipsychotics by its 10 times greater affinity for D3 receptors. This mechanism of action could be especially favorable on patients with predominant negative symptoms. This report is showing three clinical cases of acute schizophrenia exacerbation that required hospitalization and were successfully treated with cariprazine. All of them had predominant positive symptoms and two of them had substance use. Efficacy of cariprazine was also crucial on negative and cognitive symptoms with excellent tolerability.

Keywords: schizophrenia, cariprazine, antipsychotics, negative symptoms, case report

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]